Open AccessA low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity
Author(s) -
Şakir Akın,
Paula Schriek,
Cees van Nieuwkoop,
Rugina I. Neuman,
Iwan A. Meynaar,
E. J. van Helden,
Hassan El Bouazzaoui,
Rémon Baak,
Marjan Veuger,
Ronne A.T.A. Mairuhu,
Lettie van den Berg,
Vincent van Driel,
Loes E. Visser,
Evert de Jonge,
Ingrid M. Garrelds,
Johannes F A B Duynstee,
Jan Kees van Rooden,
Jeroen Ludikhuize,
Koen Verdonk,
Kadir Çalışkan,
Tim C. Jansen,
Ron H. N. van Schaik,
A.H. Jan Danser
Publication year - 2021
Publication title -
journal of hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.249
H-Index - 172
eISSN - 1473-5598
pISSN - 0263-6352
DOI - 10.1097/hjh.0000000000003054
Subject(s) - renin–angiotensin system , medicine , aldosterone , tmprss2 , angiotensin converting enzyme 2 , plasma renin activity , peptidyl dipeptidase a , endocrinology , genotype , covid-19 , gene , biology , blood pressure , genetics , disease , infectious disease (medical specialty)
The severity of COVID-19 after SARS-CoV-2 infection is unpredictable. Angiotensin-converting enzyme-2 (ACE2) is the receptor responsible for coronavirus binding, while subsequent cell entry relies on priming by the serine protease TMPRSS2 (transmembrane protease, serine 2). Although renin-angiotensin-aldosterone-system (RAAS) blockers have been suggested to upregulate ACE2, their use in COVID-19 patients is now considered well tolerated. The aim of our study was to investigate parameters that determine COVID-19 severity, focusing on RAAS-components and variation in the genes encoding for ACE2 and TMPRSS2.